Aspire Biopharma Holdings, Inc.

Aspire is an early-stage biopharmaceutical company, incorporated in Delaware in February 2025. The company focuses on developing and marketing new sublingual (under the tongue) delivery methods, initially for existing drugs. Aspire was previously a privately held Puerto Rico corporation, incorporated in September 2021. The company plans to generate revenue by developing and marketing drugs and nutraceuticals using its novel sublingual delivery technology. Aspire may also enter into license or collaboration agreements with other companies, which could include development funding, upfront and milestone payments, and/or royalties. Currently, Aspire does not have any licensing or collaboration agreements. Aspire relies on third parties for the manufacture of its product candidates for preclinical studies, clinical trials, and sales, and plans to continue this approach. The company does not own or operate manufacturing facilities and has no current plans to build its own clinical or commercial scale manufacturing capabilities. To meet future commercial manufacturing needs, current third-party manufacturers will need to increase their production, or Aspire will need to find alternative suppliers. Aspire has personnel with manufacturing experience to manage its relationships with contract manufacturers. In the fourth quarter of 2024, Aspire entered into a development and manufacturing agreement with Glatt, a contract manufacturer. Under this agreement, Glatt produced enough of Aspire's high-dose sublingual aspirin product, informally referred to as "Instaprin," for the clinical trials required to obtain U.S. Food and Drug Administration (FDA) approval to market the product and complete clinical trials.